

# FP7 Cooperation Work Programme: Theme 1 - Health

## Call Fiche

- Call identifier: FP7-HEALTH-2007-A
- Date of publication: 22 December 2006
- Deadline: 19 April 2007, at 17.00, Brussels local time
- Indicative budget: €628 million from 2007 budget<sup>1</sup>
- Topics called:

Activity/Area	Topic	Funding scheme
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH		
1.1. HIGH-THROUGHPUT RESEARCH		
1.1.	HEALTH-2007-1.1-1: Unifying human and model organism genetic variation databases.	Collaborative project (Large-scale integrating project)
1.1.	HEALTH-2007-1.1-2: Temporal and spatial proteomics to study biological processes relevant to human health.	Collaborative project (Large-scale integrating project)
1.1.	HEALTH-2007-1.1-3: Groundbreaking techniques for DNA sequencing and genotyping.	Collaborative project (Large-scale integrating project)
1.2. DETECTION, DIAGNOSIS AND MONITORING		
1.2.	HEALTH-2007-1.2-1: Development of a hybrid imaging system.	Collaborative project (Small or medium-scale focused research project)
1.2.	HEALTH-2007-1.2-2: Novel optical methodologies for detection, diagnosis and monitoring of disease or disease-related processes.	Collaborative project (Small or medium-scale focused research project)
1.2.	HEALTH-2007-1.2-3: Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of response to therapy.	Collaborative project (Large-scale integrating project)
1.2.	HEALTH-2007-1.2-4: In vivo image-guidance for cell therapy.	Collaborative project (Large-scale integrating project)
1.3. PREDICTING SUITABILITY, SAFETY AND EFFICACY OF THERAPIES		
1.3.	HEALTH-2007-1.3-1: Novel alternative testing strategies for use in pharmaceutical discovery and development.	Collaborative project (Large-scale integrating project)
1.3.	HEALTH-2007-1.3-2: Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development.	Coordination and support action (Coordination or support action)
1.3.	HEALTH-2007-1.3-3: Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology.	Collaborative project (Small or medium-scale focused research project)
1.3.	HEALTH-2007-1.3-4: Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics.	Collaborative project (Small or medium-scale focused research project)
1.3.	HEALTH-2007-1.3-5: In silico modelling for ADMET outcomes.	Collaborative project (Large-scale integrating project)
1.4. INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS		
1.4.	HEALTH-2007-1.4-1: Development and production of new generation antibodies.	Collaborative project (Small or medium-scale focused research project)
1.4.	HEALTH-2007-1.4-2: Innovative approaches for the development of vaccines for young children.	Collaborative project (Small or medium-scale focused research project)
1.4.	HEALTH-2007-1.4-3: Immunotherapy of human food allergies.	Collaborative project (Small or medium-scale focused research project)

<sup>1</sup> Under the condition that the preliminary draft budget for 2007 is adopted without modifications by the budget authority.

2. TRANSLATING RESEARCH FOR HUMAN HEALTH		
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY		
2.1.1. Large scale data gathering		
2.1.1.	HEALTH-2007-2.1.1-1: Networking biobanking initiatives across Europe: developing standards and norms for existing and future human sample biobanks.	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-2: Molecular epidemiological studies in existing well characterised European (and/or other) population cohorts.	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-3: Comparative studies of genetic variation in humans: towards a reference population in Europe.	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-4: Characterisation and variability of the microbial communities in the Human Body	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-5: Structure-function analysis of membrane-transporters and channels for the identification of potential drug target sites.	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-6: High throughput analysis of lipids and lipid-protein interactions.	Collaborative project (Large-scale integrating project)
2.1.1.	HEALTH-2007-2.1.1-7: Genome-wide association studies in mammalian non-rodent models for the identification of genes relevant to human health and disease.	Collaborative project (Large-scale integrating project)
2.1.2. Systems biology		
2.1.2.	HEALTH-2007-2.1.2-1: A system approach to eukaryotic unicellular organism biology.	Collaborative project (Large-scale integrating project)
2.1.2.	HEALTH-2007-2.1.2-2: Modelling of T-cell activation.	Collaborative project (Large-scale integrating project)
2.1.2.	HEALTH-2007-2.1.2-3: Fundamental approaches to stem cell differentiation.	Collaborative project (Large-scale integrating project)
2.1.2.	HEALTH-2007-2.1.2-4: Developing an integrated in vitro, in vivo and systems biology modelling approach to understanding apoptosis in the context of health and disease	Collaborative project (Large-scale integrating project)
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING		
2.2.1. Brain and brain-related diseases		
2.2.1.	HEALTH-2007-2.2.1-1: Stroke and mechanisms underlying ischemic brain damage.	Collaborative project (Large-scale integrating project)
2.2.1.	HEALTH-2007-2.2.1-2: Coding in neuronal assemblies.	Collaborative project (Small or medium-scale focused research project)
2.2.1.	HEALTH-2007-2.2.1-3: Neurobiology of anxiety disorders.	Collaborative project (Small or medium-scale focused research project)
2.2.1.	HEALTH-2007-2.2.1-4: Memory loss: underlying mechanisms and therapy.	Collaborative project (Small or medium-scale focused research project)
2.2.1.	HEALTH-2007-2.2.1-5: From basic spinal mechanisms to spinal cord disease and trauma.	Collaborative project (Small or medium-scale focused research project)
2.2.1.	HEALTH-2007-2.2.1-6: Neuron-glia interactions in health and disease.	Collaborative project (Small or medium-scale focused research project)
2.2.2. Human development and ageing		
2.2.2.	HEALTH-2007-2.2.2-1: Novel approaches to reconstitute normal immune function at old age.	Collaborative project (Large-scale integrating project)
2.2.2.	HEALTH-2007-2.2.2-2: Termination of developmental processes and their reactivation in adult life.	Collaborative project (Large-scale integrating project)
2.2.2.	HEALTH-2007-2.2.2-3: Biomarkers of ageing.	Collaborative project (Large-scale integrating project)
2.2.2.	HEALTH-2007-2.2.2-4: Increasing the participation of elderly in clinical trials.	Coordination and support action (Coordination or support action)
2.2.2.	HEALTH-2007-2.2.2-5: Research on human development and/or healthy ageing across the EU	Coordination and support action (Coordination or support action)

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH		
2.3.1 Anti-microbial drug resistance including fungal pathogens		
2.3.2. HIV/AIDS, malaria and tuberculosis		
2.3.2.	HEALTH-2007-2.3.2-1: HIV/AIDS Drug Discovery and Preclinical Development.	Collaborative project (Small or medium-scale focused research project)
2.3.2.	HEALTH-2007-2.3.2-2: Highly innovative approaches for research into host-pathogen interaction in tuberculosis.	Collaborative project (Small or medium-scale focused research project)
2.3.2.	HEALTH-2007-2.3.2-3: Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and tuberculosis and of latent tuberculosis infection (LTBI).	Collaborative project (Small or medium-scale focused research project)
2.3.2.	HEALTH-2007-2.3.2-4: Addressing knowledge gaps in pregnancy malaria.	Collaborative project (Small or medium-scale focused research project)
2.3.2.	HEALTH-2007-2.3.2-5: Paediatric formulations of drugs against HIV/AIDS, malaria and tuberculosis.	Coordination and support action (Coordination or support action)
2.3.2.	HEALTH-2007-2.3.2-6: New HIV Vaccines inducing broadly-reactive neutralising antibodies.	Collaborative project (Large-scale integrating project)
2.3.3. Potentially new and re-emerging epidemics		
2.3.3.	HEALTH-2007-2.3.3-1: Development of broadly protective influenza vaccine candidates.	Collaborative project (Small or medium-scale focused research project)
2.3.3.	HEALTH-2007-2.3.3-2: Identifying immunological mechanisms of protection for influenza vaccines.	Collaborative project (Small or medium-scale focused research project)
2.3.3.	HEALTH-2007-2.3.3-3: Standardisation of immunological assays including surrogate markers for evaluation of new influenza vaccines in clinical trials.	Coordination and support action (Coordination or support action)
2.3.3.	HEALTH-2007-2.3.3-4: Innovative point-of-care diagnostic tests for influenza.	Collaborative project (Small or medium-scale focused research project targeted to SMEs)
2.3.3.	HEALTH-2007-2.3.3-5: Development of additional treatment strategies for patients suffering from highly pathogenic influenza.	Collaborative project (Small or medium-scale focused research project)
2.3.3.	HEALTH-2007-2.3.3-6: Development of pandemic influenza containment and mitigation strategies.	Collaborative project (Small or medium-scale focused research project)
2.3.3.	HEALTH-2007-2.3.3-7: Supporting highly innovative interdisciplinary research on influenza.	Collaborative project (Small or medium-scale focused research project)
2.3.3.	HEALTH-2007-2.3.3-8: Influenza research in collaboration with Asian partners.	SICA: Collaborative project (Small or medium-scale focused research project)
2.3.4. Neglected infectious diseases		
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES		
2.4.1. Cancer		
2.4.1.	HEALTH-2007-2.4.1-1: Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel diagnosis and therapy strategies.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-2: Translating clinical 'omics'-technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-3: Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-4: Novel cancer screening methods.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-5: Optimising research on end of life care of cancer patients.	Coordination and support action (Coordination action)

2.4.1.	HEALTH-2007-2.4.1-6: Understanding and fighting metastasis.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-7: Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy.	Collaborative project (Small or medium-scale focused research project)
2.4.1.	HEALTH-2007-2.4.1-8: Developing high-throughput bioassays and models for human cancers in lower species.	Collaborative project (Small or medium-scale focused research project)
2.4.2. Cardiovascular disease		
2.4.2.	HEALTH-2007-2.4.2-1: Molecular basis of the inflammatory response and associated vascular remodelling in arteriosclerosis.	Collaborative project (Large-scale integrating project)
2.4.2.	HEALTH-2007-2.4.2-2: Vascular remodelling in aneurysmal disease.	Collaborative project (Large-scale integrating project)
2.4.2.	HEALTH-2007-2.4.2-3: Combating stroke.	Collaborative project (Large-scale integrating project)
2.4.3. Diabetes and obesity		
2.4.3.	HEALTH-2007-2.4.3-1: Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention.	Collaborative project (Small or medium-scale focused research project)
2.4.3.	HEALTH-2007-2.4.3-2: Combined forms of diabetes in children.	Collaborative project (Small or medium-scale focused research project)
2.4.3.	HEALTH-2007-2.4.3-3: Insulin resistance as a key factor in the development of diabetes and metabolic syndrome.	Collaborative project (Small or medium-scale focused research project)
2.4.3.	HEALTH-2007-2.4.3-4: Pathophysiological mechanisms related to excess fat.	Collaborative project (Small or medium-scale focused research project)
2.4.3.	HEALTH-2007-2.4.3-5: A road-map for diabetes research.	Coordination and support action (Coordination or support action)
2.4.4. Rare diseases		
2.4.4.	HEALTH-2007-2.4.4-1: Natural course and pathophysiology of rare diseases.	Collaborative project (Small or medium-scale focused research project)
2.4.4.	HEALTH-2007-2.4.4-2: Research capacity-building in the field of rare diseases.	Coordination and support action (Coordination or support action)
2.4.5. Other chronic diseases		
2.4.5.	HEALTH-2007-2.4.5-1: Osteoarthritis.	Collaborative project (Large-scale integrating project)
2.4.5.	HEALTH-2007-2.4.5-2: Inflammatory bowel disease.	Collaborative project (Small or medium-scale focused research project)
2.4.5.	HEALTH-2007-2.4.5-3: Osteoporosis: signalling pathways in bone formation and homeostasis.	Collaborative project (Small or medium-scale focused research project)
2.4.5.	HEALTH-2007-2.4.5-4: Genetic factors of Osteoporosis.	Collaborative project (Small or medium-scale focused research project)
2.4.5.	HEALTH-2007-2.4.5-5: Intervertebral disc degeneration: prevention and repair.	Collaborative project (Small or medium-scale focused research project)
2.4.5.	HEALTH-2007-2.4.5-6: Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD).	Collaborative project (Small or medium-scale focused research project)
2.4.5.	HEALTH-2007-2.4.5-7: Hearing impairment and degeneration.	Coordination and support action (Coordination or support action)
2.4.5.	HEALTH-2007-2.4.5-8: Impairment of touch and proprioception at old age.	Coordination and support action (Coordination or support action)
2.4.5.	HEALTH-2007-2.4.5-9: Visual impairment and degeneration.	Coordination and support action (Coordination or support action)

4. OTHER ACTIONS ACROSS THE HEALTH THEME		
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME		
4.1.	HEALTH-2007-4.1-1: Reinforcing the network of National Contact Points (NCP) for the Seventh Framework Programme under Health Theme by promoting trans-national co-operation.	Coordination and support action (Coordination or support action)
4.1.	HEALTH-2007-4.1-2: Promoting participation of high-technology research intensive SMEs, operating in the biomedical engineering and other medical technology sectors relevant to Health Theme.	Coordination and support action (Support action)
4.1.	HEALTH-2007-4.1-3: Assessment and valorisation of project outcome for high-technology and research intensive SME participating to Framework Programmes of Research in the healthcare sector.	Coordination and support action (Support action)
4.1.	HEALTH-2007-4.1-4: Identifying patients' needs in the clinical trials context.	Coordination and support action (Coordination or support action)
4.1.	HEALTH-2007-4.1-5: Science communication actions.	Coordination and support action (Support action)
4.1.	HEALTH-2007-4.1-6: Initiatives to foster dialogue and debate on health research issues of interest to the public.	Coordination and support action (Support action)
4.1.	HEALTH-2007-4.1-7: Studies on impact of EU legislations on health research and related developments and applications.	Coordination and support action (Support action)
4.2. RESPONDING TO EU POLICY NEEDS		
4.2.	HEALTH-2007-4.2-3: Research to assess the economic dimension of occupational health and safety.	Coordination and support action (Support action)
4.2.	HEALTH-2007-4.2-4: Health statistics and rare events.	Collaborative project (Small or medium-scale focused research project)

- Evaluation procedure:

- The general eligibility criteria are set out in Annex 2 to this work programme.
- A one-stage submission procedure will be followed.
- Proposals may be evaluated remotely.
- The evaluation criteria (including weights and thresholds) and subcriteria, together with the eligibility, selection and award criteria, for the different funding schemes are set out in Annex 2 to this work programme.

- Indicative evaluation and contractual timetable:

Evaluations are expected to be carried out during the months May-July 2007. It is expected that the contract negotiations for the shortlisted proposals will be opened in July/August.

- Consortium agreements: Participants in Large-scale integrating projects are required to conclude a consortium agreement.
- Particular requirements for participation, evaluation and implementation:

**It is important to note that the following funding thresholds will be applied as eligibility criteria and that the proposals which do not respect these limits will be considered as ineligible:**

- Small or medium-scale focused research projects: the requested EC contribution shall not exceed € 3 million unless otherwise indicated in the topic description.
- Large-scale integrating projects: the requested EC contribution shall be over € 6 million and not exceed € 12 million unless otherwise indicated in the topic description.

The minimum number of participating legal entities required, for all funding schemes, is set out in the Rules for Participation and presented in relevant parts below.

<b>Funding scheme</b>	<b>Minimum conditions</b>
Collaborative project	At least 3 independent legal entities, each of which is established in a MS or AC, and no two of which are established in the same MS or AC.
Collaborative project for specific cooperation actions dedicated to international cooperation partner countries (SICA)	At least 4 independent legal entities. Of these, 2 must be established in different MS or AC. The other two must be established in different international cooperation partner countries
Co-ordination and support action (coordination action)	At least 3 independent legal entities, each of which is established in a MS or AC, and no two of which are established in the same MS or AC.
Co-ordination and support action (support action)	At least 1 independent legal entity
Research for the benefit of specific groups, such as SMEs	At least 3 independent legal entities, each of which is established in a MS or AC, and no two of which are established in the same MS or AC.

For Small or medium-scale focused research projects targeted to SMEs all consortia should aim at having 40 % of the requested EC contribution budget going to SMEs.

- The forms of grant and maximum reimbursement rates which will be offered are specified in Annex 3 to the Cooperation work programme.